Skip to content
Projects
Groups
Snippets
Help
Loading...
Help
Submit feedback
Sign in / Register
Toggle navigation
C
cmscenter
Project
Project
Details
Activity
Releases
Cycle Analytics
Repository
Repository
Files
Commits
Branches
Tags
Contributors
Graph
Compare
Charts
Issues
0
Issues
0
List
Board
Labels
Milestones
Merge Requests
0
Merge Requests
0
Wiki
Wiki
Snippets
Snippets
Members
Members
Collapse sidebar
Close sidebar
Activity
Graph
Charts
Create a new issue
Commits
Issue Boards
Open sidebar
吕祺
cmscenter
Commits
3822007c
Commit
3822007c
authored
Oct 08, 2021
by
chloe
Browse files
Options
Browse Files
Download
Email Patches
Plain Diff
Create article “星药科技李成涛”
parent
f3f3a9cc
Changes
2
Pipelines
1
Hide whitespace changes
Inline
Side-by-side
Showing
2 changed files
with
25 additions
and
0 deletions
+25
-0
星药科技李成涛.md
content/article/星药科技李成涛.md
+25
-0
abstract_lichengtao_21-01-26.jpg
static/img/abstract_lichengtao_21-01-26.jpg
+0
-0
No files found.
content/article/星药科技李成涛.md
0 → 100644
View file @
3822007c
---
title
:
星药科技李成涛
type
:
榕问CEO
createDate
:
2021-10-08T08:42:44.553Z
content
:
>-
一直以来新药研发有着投入高、耗时长、风险高三大痛点,加上近年来仿制药行业面临洗牌,AI+新药研发备受关注。
星药科技成立于2019年,致力于用世界领先的人工智能技术推动新药研发。通过人工智能药物发现平台,帮助药物研发科学家大幅节省药物开发环节的时间和成本。
世界上可能成药的化合物量级约为10的60次方。也因此,星药科技把研发新药的过程比喻是在浩瀚的化合物宇宙中找到可以治愈的“钥匙”,而人工智能技术则可以帮助我们更快、更好地发现这些“钥匙”。
高榕资本曾于2019年领投星药科技天使轮融资,并在后续轮持续投资。目前,星药科技已取得了多项重大技术突破,其自主研发的模型和算法在多个环节中均取得了相关领域的最好成绩,能够极大缩短药物研发时间和成本,直指新药研发难题。
星药科技创始人、CEO李成涛博士,围绕新药研发行业痛点、人工智能赋能新药研发、跨领域科研等话题,分享了他的思考。
<video src="https://gaorongfile.blob.core.chinacloudapi.cn/ronghui/%E6%98%9F%E8%8D%AF%E7%A7%91%E6%8A%80%E6%9D%8E%E6%88%90%E6%B6%9B.mp4" poster="/static/img/abstract_lichengtao_21-01-26.jpg" controls="controls">
</video>
-
--
static/img/abstract_lichengtao_21-01-26.jpg
0 → 100644
View file @
3822007c
This diff is collapsed.
Click to expand it.
Write
Preview
Markdown
is supported
0%
Try again
or
attach a new file
Attach a file
Cancel
You are about to add
0
people
to the discussion. Proceed with caution.
Finish editing this message first!
Cancel
Please
register
or
sign in
to comment